UBS Group’s Zymeworks ZYME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.3M Sell
171,779
-107,075
-38% -$2.53M ﹤0.01% 4227
2025
Q4
$7.34M Buy
278,854
+227,013
+438% +$4.95M ﹤0.01% 3626
2025
Q3
$885K Sell
51,841
-199,669
-79% -$2.86M ﹤0.01% 5674
2025
Q2
$3.16M Buy
251,510
+37,210
+17% +$443K ﹤0.01% 4342
2025
Q1
$2.55M Buy
214,300
+47,404
+28% +$646K ﹤0.01% 4487
2024
Q4
$2.44M Buy
166,896
+31,341
+23% +$438K ﹤0.01% 4539
2024
Q3
$1.7M Buy
135,555
+9,881
+8% +$108K ﹤0.01% 4156
2024
Q2
$1.07M Buy
125,674
+58,250
+86% +$519K ﹤0.01% 4362
2024
Q1
$709K Buy
67,424
+3,010
+5% +$33.4K ﹤0.01% 4901
2023
Q4
$669K Buy
64,414
+26,594
+70% +$212K ﹤0.01% 4843
2023
Q3
$240K Buy
37,820
+7,432
+24% +$54.9K ﹤0.01% 5235
2023
Q2
$263K Buy
30,388
+15,322
+102% +$137K ﹤0.01% 5296
2023
Q1
$136K Buy
15,066
+15,041
+60,164% +$131K ﹤0.01% 5673
2022
Q4
$197 Hold
25
﹤0.01% 10321
2022
Q3
$0 Hold
25
﹤0.01% 11023
2022
Q2
$0 Hold
25
﹤0.01% 11043
2022
Q1
$0 Sell
25
-3,571
-99% -$31.8K ﹤0.01% 11002
2021
Q4
$59K Buy
3,596
+3,246
+927% +$67.7K ﹤0.01% 6757
2021
Q3
$10K Sell
350
-430
-55% -$14.3K ﹤0.01% 8024
2021
Q2
$28K Sell
780
-8,328
-91% -$264K ﹤0.01% 7011
2021
Q1
$287K Buy
9,108
+1,493
+20% +$60.7K ﹤0.01% 5235
2020
Q4
$359K Buy
7,615
+1,604
+27% +$74.5K ﹤0.01% 4850
2020
Q3
$280K Buy
6,011
+1,290
+27% +$44.3K ﹤0.01% 4592
2020
Q2
$170K Sell
4,721
-2,680
-36% -$98.7K ﹤0.01% 4916
2020
Q1
$263K Sell
7,401
-22,638
-75% -$926K ﹤0.01% 4505
2019
Q4
$1.37M Sell
30,039
-12,328
-29% -$448K ﹤0.01% 3921
2019
Q3
$1.05M Buy
42,367
+40,476
+2,140% +$1.01M ﹤0.01% 3927
2019
Q2
$42K Buy
1,891
+768
+68% +$14.1K ﹤0.01% 6074
2019
Q1
$18K Buy
+1,123
New +$17.4K ﹤0.01% 6400
2018
Q4
Sell
-2,386
Closed -$37K 8353
2018
Q3
$37K Buy
+2,386
New +$34.1K ﹤0.01% 6401
2018
Q2
Sell
-440
Closed -$5K 8308
2018
Q1
$5K Sell
440
-372
-46% -$4.02K ﹤0.01% 7251
2017
Q4
$6K Buy
+812
New +$6.67K ﹤0.01% 7323

Other funds holding ZYME

UBS Group's ZYME Position: Q1 2026 in Review

UBS Group reduced its Zymeworks (ZYME) stake by 38% in Q1 2026, selling an estimated $2.53M and leaving 171,779 shares worth $4.3M. The position accounts for ﹤0.01% of the portfolio, ranked #4227.

UBS Group first reported a position in ZYME in Q4 2017 and has held it in 32 quarters since. The position peaked at $7.34M in Q4 2025. 211 funds tracked by Wall St. Rank hold ZYME as of Q1 2026.

  • UBS Group held 171,779 shares of Zymeworks worth $4.3M as of Q1 2026.
  • UBS Group sold 107,075 Zymeworks shares in Q1 2026, an estimated $2.53M.
  • Zymeworks made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4227 holding.
  • UBS Group first reported a position in Zymeworks in Q4 2017 and has held it in 32 quarters since.
  • UBS Group's Zymeworks position peaked at $7.34M in Q4 2025.
  • 211 funds tracked by Wall St. Rank held Zymeworks as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.